Companies › Zhejiang Hanmai Pharmaceutical Technology
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 1; Neurology, Metabolic and endocrine; next expected readout Aug 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| YJ001 for Spray Use | – | Phase 3 | Diabetic Peripheral Neuropathic Pain (DPNP); Diabetic Peripheral Neuropathic Pain | Aug 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06361108 | YJ001 for Spray Use | Phase 1 | Diabetic Peripheral Neuropathic Pain | Metabolic and endocrine | Dec 2025 |
| NCT07859111 | YJ001 for Spray Use | Phase 3 | Diabetic Peripheral Neuropathic Pain (DPNP) | Neurology | Aug 2028 |
No annotated target.
–
IntraBio Upsher-Smith Laboratories Urovant Sciences Shenzhen Wingor Biotechnology NeuroBiogen
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.